Strategies and results of oncofertility counseling in young breast cancer patients by Kufel-Grabowska, Joanna et al.
263
Original article
NOWOTWORY Journal of Oncology 
2021, volume 71, number 5, 263–266
DOI: 10.5603/NJO.2021.0053
© Polskie Towarzystwo Onkologiczne
ISSN 0029–540X, e-ISSN: 2300-2115
www.nowotwory.edu.pl
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Strategies and results of oncofertility counseling in young 
breast cancer patients
Joanna Kufel-Grabowska1, 2, Piotr Jędrzejczak3, Mikołaj Bartoszkiewicz4, Paweł Burchardt5,  
Maria Litwiniuk6, 7
1Department of Electroradiology, Poznan University of Medical Sceinces, Poznan, Poland 
2Department of Chemotherapy, University Hospital of Lord's Transfiguration, Poznan, Poland
3Department of Infertility and Reproductive Endocrinology, Poznan University of Medical Sciences, Poznan, Poland
4Department of Immunobiology, Poznan University of Medical Sciences, Poznan, Poland;
5Department of Hypertension, Angiology and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland 
6Department of Chemotherapy, Greater Poland Cancer Center, Poznan, Poland
7Department of Cancer Pathology and Prevention, Poznan University of Medical Sciences, Poznan, Poland
Introduction. Breast cancer (BC) is the most common female neoplasm in Poland and worldwide, yet up to 7% of all 
cases is diagnosed &lt; 40 years of age. The increased BC morbidity rate in this age group as well as hope for late maternity 
need special attention. 
Material and methods.  The data concerning the number of children and further procreation needs in women (n = 68), 
aged 18–40, diagnosed and treated for early breast cancer at the Greater Poland Cancer Center in 2018–2019, were taken 
from patients’ histories by an oncologist before (neo-)adjuvant systemic therapy.
Results.  Out of the 68 females surveyed, aged 18–40 (median age 36), 14 (21%) were childless at the moment of diagno-
sis. After being informed about the therapy, prognosis, side effects and oncofertility, 12 patients (18%) decided to have 
a consultation with a specialist in reproductive medicine; 5 of them (7%) already had children. In 2 women (3%), hormo-
nal stimulation in combination with tamoxifen was used; then, oocytes were collected and cryopreserved. In 19 (28%), 
gonadotropine analogues were added to (neo-)adjuvant chemotherapy. In 17 patients (25%) pathogenic mutations in 
BRCA1/2 genes were found.
Conclusions.  Oncofertility counseling in young BC patients should be one of the fundamental elements of complex 
patient care. 
Key words:  oncofertility, breast cancer, BRCA1/2 mutation, young women
How to cite:
Kufel-Grabowska J, Jędrzejczak P, Bartoszkiewicz M, Burchardt P, Litwiniuk M. Strategies and results of oncofertility counseling in young breast cancer patients 
NOWOTWORY J Oncol 2021; 71: 263–266. 
Introduction
Breast cancer is the most frequently diagnosed cancer 
among women in Poland and in the world, but it rarely 
occurs in young women. Patients under 40 years of age 
constitute about 7% of all cases. The prognosis for young 
women is worse than that of older women mainly due to 
the more frequent occurrence of unfavorable phenotypes 
of breast cancer and the presence of numerous genetic 
disorders in the tumor tissue, which is the reason for the 
more aggressive course of the disease [1]. In addition, at 
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the time of diagnosis, young women are more often dia-
gnosed with more advanced disease than older women. 
The therapy of breast cancer, apart from surgery, often re-
quires complementary treatment: chemotherapy, hormone 
therapy or radiotherapy. Systemic treatment is more likely to 
temporarily or irreversibly impair fertility than other cancers, 
which may be due in part to the duration of breast cancer 
therapy (up to 10 years) [2]. 
Diagnosis of breast cancer may have devastating effects 
on a woman and her loved ones, and affects every sphere of 
their lives. In the case of young women, it often occurs during 
the period of starting a family and planning offspring. The pro-
spect of having to undergo cancer treatment and the desire 
to have children should not be mutually exclusive, and any 
woman in her reproductive years who expresses a desire to 
have children should have a consultation with a reproductive 
medicine specialist before starting treatment, preferably im-
mediately after breast cancer diagnosis. If the consultation is 
delayed, the chances of fertility preservation after treatment 
are reduced [2].
The oncologist’s role is to present the patient with a tre-
atment plan, and to inform her about the possible effects of 
therapy, including the potential impact on ovarian dysfunction. 
The stress associated with a cancer diagnosis causes woman to 
postpone procreation plans, and instead focus on the cancer 
therapy. For most patients with early breast cancer, postponing 
therapy by 3–4 weeks does not affect prognosis. During this 
time, patients can take care of fertility preservation and enjoy 
motherhood after treatment. A significant proportion of young 
breast cancer patients are diagnosed with a mutation in their 
genes that increases the risk of breast and ovarian cancer 
(BRCA1/2), and the only treatment to reduce the risk of develo-
ping subsequent cancers is surgery: bilateral mastectomy and 
ovariectomy [3]. Carrying pathogenic mutations in BRCA1/2 
genes by the patient can impact decisions to have offspring 
after breast cancer therapy and before ovarian removal.
Objective
The aim of this paper was to assess the interest of young 
patients with early breast cancer in fertility preservation tech-
niques, treated in the Chemotherapy Outpatient Clinic of the 
Greater Poland Cancer Center, Poznan, Poland, in consultation 
with a reproductive medicine specialist. An additional aim 
was to draw physicians’ attention to the problem of infertility 
accompanying cancer therapy.
Material and methods
It was a retrospective study. Patients with early breast cancer 
aged 18–40 years who were treated in the Chemotherapy 
Outpatient Clinic of the Greater Poland Cancer Center at 
Poznan, Poland during 2018–2019 and informed about the 
possibility of fertility preservation techniques were covered 
with the study. Medical data were obtained from medical 
history regarding age, offspring, desire to have children in 
the future, consultation with a reproductive medicine spe-
cialist, and fertility preservation techniques used, as well as 
carrying pathogenic mutations in genes that increase breast 
cancer risk. Fertility preservation techniques included ova-
rian stimulation, oocyte collection and freezing, as well as 
the inclusion of gonadotropin-releasing hormone analoges 
during systemic treatment.
Statistic
The IBM SPSS Statistics 26 program was used for the ana-
lysis. The significance level was adopted as 0.05. The 
Shapiro-Wilk test was used to test the normality of data di-
stribution. The nonparametric Mann-Whitney U test was used 
to compare the data distributions (due to the lack of normal 
data distribution). The chi-square test and z-test were used 
to investigate correlations.
Ethics
An oncologist and gynecologist’s analysis of patient records 
does not require the opinion of a bioethical committee.
Results
66 patients with early breast cancer who underwent treat-
ment in the Chemotherapy Outpatient Clinic of the Greater 
Poland Cancer Center at Poznan, Poland during 2018–2019 
were included in the analysis. The median age of patients 
was 36 years (26–40 years). All patients were informed by the 
treating physician about the potential effects of systemic tre-
atment and the possibility of fertility preservation techniques 
prior to systemic treatment. Those who received consultation 
with a reproductive medicine specialist were characterized by 
their younger age (33.5 vs. 36.5 years).
At the time of treatment planning for early breast cancer, 
14 patients (20.6%) had no children. After discussion with the 
oncologist about prognosis, treatment plan, and the possibi-
lity of complications, including infertility, 12 patients (17.6%) 
decided to have a consultation with a reproductive medicine 
specialist; among those without children (n = 14 patients), 
half (n = 7 patients, 50%) had a consultation with a specialist, 
whereas among those with at least one child, less than 10% 
(n= 5 of a group of n = 54 patients; 9.3%) decided to have 
such a consultation. 19 patients (27.9%) were treated with 
gonadotropin-releasing hormone (GnRH) analoges, while 
2 patients (2.9%) underwent hormonal stimulation combined 
with tamoxifen, followed by oocyte collection and freezing 
(tab. I).
Table I. Applied fertility preservation techniques
Fertility preservation techniques No. of patients (%)
oocyte freezing n = 2 (2.9)
use of GnRH n = 19 (27.9)
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The majority of patients had genetic counseling (54–79.4%). 
6 patients (10.3%) had a test for founder mutations in BRCA1 
gene, 32 patients (47.1%) had an extended test for further mu-
tations in BRCA1/2 genes as well as in CHEK2 and PALB genes, 
15 patients (22.1%) had performed Next Generation Sequen-
cing (NGS) of BRCA1/2 genes or a multigene test, and 16 pa-
tients (23.5%) had no genetic test results found in their medical 
history (tab. II). In 17 patients (25%), pathogenic mutations were 
found in BRCA1/2 genes.
No significant age differences were observed between 
BRCA1/2 gene mutation carriers and patients without the 
identified mutation (average 34.24 vs. 35.87; median 34 vs. 36). 
Patients who were carriers of mutations in BRCA1/2 genes were 
less likely (n = 12; 70.6%) to consult a reproductive medicine 
specialist than patients without known mutations (n = 46; 
86.8%), but no statistical significance was found. None of the 
BRCA1/2 mutation carriers opted for oocyte freezing.
Among the women with BRCA1/2 mutation, the GnRH 
analogues were used in 10 individuals (58.8%), whereas among 
those without BRCA1/2 mutation, the GnRH analogues were 
included in 8 individuals (19%) which was statistically signifi-
cant (tab. III).
Discussion
Breast cancer in young women is rare, but the prognosis is po-
orer than in older women regardless of biological subtype. This 
includes a higher stage of the disease at the time of referral to 
the physician due to the glandular structure of the breast and 
associated diagnostic difficulties. More aggressive biological 
subtypes (triple-negative carcinoma, without expression of 
hormone receptors and without overexpression of the HER2 
receptor or amplification of its gene, HER2-positive carcinoma 
showing overexpression of the HER2 receptor or amplification 
of its gene) and other molecular background are more com-
mon in young women than in older breast cancer patients 
[4]. Young women are even over ten times more likely to be 
diagnosed with pathogenic mutations in genes that increase 
the risk of breast and ovarian cancer (BRCA1/2) than older 
women (2.5% vs. 25%) [5]. In the European Union, the average 
age at which the first child is born is 29.3 years, which means 
that often the diagnosis of breast cancer occurs among wo-
men who have not yet completed childbearing and are still 
planning offspring [6]. 
The principal treatment for breast cancer is surgery, but 
complementary treatments (chemotherapy, immunotherapy, 
hormone therapy, or radiotherapy) are also often used. Systemic 
treatment can significantly impair a woman’s reproductive func-
tion, leading to temporary or irreversible infertility. The impair-
ment of ovarian function depends on the patient’s age, type of 
chemotherapy used, and the dose of drugs given. The commonly 
used perioperative chemotherapy involves anthracyclines and 
taxanes (4 x doxorubicin + cyclophosphamide, 12 x paclitaxel), and 
cytostatic drugs with an intermediate risk of causing permanent 
infertility in women. Infertility is always related with menopause 
induced changes like sexual distress. Chemotherapy-induced 
menopause symptoms can be more pronounced. Physiological 
menopause is a process, which lasts for many months, while iatro-
genic menopause affects young patients experiencing a sudden 
decrease in estrogen level within a short time [7]. 
The authors of a paper published in July 2020 in the jo-
urnal JAMA emphasize that despite ASCO recommendations, 
less than half of patients (44%) with cancer of reproductive 
age  –  women aged 18 to 40, men aged 18 to 50 – were 
informed about the possibility of fertility disorders caused 
by cancer treatment and the possibility of consultation with 
a reproductive medicine specialist. This was more often the 
case for young, female patients, especially those suffering from 
breast cancer or hematological malignancies. Patients treated 
Table II. Test results found in medical history
Type of test No. of patients
test for founder mutations in BRCA1 gene 
(c.5266dupC, c.4035delA, c.181T>G, c. 3700_3704delGTAAA, c.68_69delAG)
n = 7 (10.3%)
test extended to include further mutations in BRCA1/2 + CHEK2 + PALB genes (749delT(c.675delT), 185delAG (c.68_69delAG), 
5370>T (c.5251>T), 3819del5 (c.3700_3704delGTAAA), 3875del4 (c.3756_3759delGTCT), 8138del5 (c.7910_7914delCCTTT), 
886delGT (c.658_659deGT), 6174delT (c.5946delT), 5467insT (c.5239_5240insT), 4075delGT (c.3847_3848delGT)  
CHEK2 gene (c.1100delC, del5395, c.444+1G>A, p.I157T)  
PALB gene (c.172_175delITTGT, c.509_510delGA) 
n = 32 (47.1%)
next generation sequencing (NGS) of BRCA1/2 genes or multigene test n = 15 (22.1%)
Table III. Characteristics of patients according to genetic load








Oocyte freezing Use of GnRH(%) 
analogues 
current mutation n = 17 (25) n = 34.24 n = 34 n = 0 n = 10 (58.8)
no mutation n = 35 (51.5) n = 35.87 n = 36 n = 2 (5.7) n = 8 (19%)
no medical history n = 16 (23.5)
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in academic centers or in places where fertility preservation 
procedures were reimbursed were better informed [8]. 
Also, according to the guidelines of Polish scientific so-
cieties, every patient with breast cancer of reproductive age 
should be informed about the possible complications of syste-
mic treatment, including fertility disorders, which is confirmed 
by the results of our study [9]. The vast majority of patients 
qualified for the study, almost 80%, had children. Twelve had 
a consultation with a reproductive medicine specialist, and 
5 of them had already become mothers. Despite the patients’ 
interest in fertility, only 2 patients decided to undergo oocyte 
freezing after oncological treatment and consultations with 
reproductive medicine specialists; this may be a result of the 
lack of reimbursement of fertility preservation procedures in 
Poland and in many countries and regions of the world.
The issue of informing patients about the problem of fertili-
ty and taking preventive measures is still unresolved. However, 
an evaluation of this problem was not the aim of this paper, 
and all patients were informed about the possibility of fertility 
disorders related to oncological treatment. 
Young patients are found to carry pathogenic mutations 
in BRCA1/2 genes far more often than older patients. BRCA1/2 
mutations increase the lifetime risk of breast cancer from 
45% to 85% and ovarian cancer from 10% to 60%. Effective 
measures to reduce the risk of breast and ovarian cancer in 
mutation carriers include a bilateral mastectomy and bilateral 
oophorectomy, which reduces the risk of cancer by 80–90%. 
Mutation carriers who qualified for our study, and were aware 
of their situation, often took advantage of consultations with 
a reproductive medicine specialist and agreed to start GnRH 
analogues during systemic treatment. The prospect of needing 
cancer-reducing surgery in the future may be a factor promp-
ting patients to implement fertility preservation procedures.
Ovarian stimulation, oocyte collection, oocyte freezing or 
fertilization and embryo freezing require postponement of the 
main oncological treatment by 3–4 weeks. The effectiveness of 
presented methods reaches 30% and is similar to the effective-
ness of in vitro fertilization in infertile couples without cancer 
history. In clinical practice, gonadotropin-releasing hormone 
analoges are also used during perioperative chemotherapy, the 
role of which is to inhibit ovarian function and thus reduce their 
susceptibility to cytostatic damage. However, the effectiveness 
of this method is limited [10].
The experience of our center highlights the importance of this 
problem and presents the decisions of patients who were offered 
the consultation of a reproductive medicine specialist and fertility 
preservation techniques. The awareness of fertility preservation 
by patients often results in reduced anxiety during therapy and 
improves cooperation between the patient and the oncologist.
Conclusions
Consultation with a reproductive medicine specialist should 
be a primary element of care for patients in their reproductive 
years who have been diagnosed with early breast cancer. 
The presence of pathogenic mutations in genes that increase 
the risk of breast and ovarian cancer (BRCA1/2) is an important 
factor in the decision to have offspring after treatment and be-
fore surgery with bilateral mastectomy and oophorectomy.
Advantages and disadvantages of the study
The study involved a homogeneous group of breast cancer 
patients. All patients were informed about the possible com-
plications of cancer treatment, including impaired fertility. 
Decisions made by patients may differ from their actual beliefs 
and wishes due to the lack of reimbursement of fertility pre-
servation procedures in Poland. The financial aspect may be 
the biggest factor for breast cancer patients to take  action.
Conflict of interest: none declared
Mikołaj Bartoszkiewicz





Received: 22 Mar 2021 
Accepted: 15 Jun 2021
References
1. Assi HA, Khoury KE, Dbouk H, et al. Epidemiology and prognosis of 
breast cancer in young women. J Thorac Dis. 2013; 5 Suppl 1: S2–S8, doi: 
10.3978/j.issn.2072-1439.2013.05.24, indexed in Pubmed: 23819024.
2. Oktay K, Harvey BE, Loren AW, et al. Fertility Preservation in Patients 
With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 
2018; 36(19): 1994–2001, doi: 10.1200/JCO.2018.78.1914, indexed in 
Pubmed: 29620997.
3. Narod SA. BRCA mutations in the management of breast cancer: the 
state of the art. Nat Rev Clin Oncol. 2010; 7(12): 702–707, doi: 10.1038/
nrclinonc.2010.166, indexed in Pubmed: 20956982.
4. Erić I, Petek Erić A, Kristek J, et al. BREAST CANCER IN YOUNG WOMEN: 
PATHOLOGIC AND IMMUNOHISTOCHEMICAL FEATURES. Acta Clin 
Croat. 2018; 57(3): 497–502, doi: 10.20471/acc.2018.57.03.13, indexed 
in Pubmed: 31168183.
5. Abdel-Razeq H, Al-Omari A, Zahran F, et al. Germline BRCA1/BRCA2 
mutations among high risk breast cancer patients in Jordan. BMC 
Cancer. 2018; 18(1): 152, doi: 10.1186/s12885-018-4079-1, indexed in 
Pubmed: 29409476.
6. EUROSTAT. Women are having their first child at an older age. https://
ec.europa.eu/eurostat/web/products-eurostat-news/-/DDN-20200515-
2 (11.02.2021).
7. Lachowicz M, Kufel-Grabowska J, Bartoszkiewicz M, et al. Sexual well 
being of breast cancer patients. Nowotwory. Journal of Oncology. 2021; 
71(4): 232–237, doi: 10.5603/njo.a2021.0038.
8. Patel P, Kohn TP, Cohen J, et al. Evaluation of Reported Fertility Prese-
rvation Counseling Before Chemotherapy Using the Quality Oncology 
Practice Initiative Survey. JAMA Netw Open. 2020; 3(7): e2010806, doi: 
10.1001/jamanetworkopen.2020.10806, indexed in Pubmed: 32678451.
9. Jassem J, Krzakowski M, Bobek-Billewicz B, et al. Rak piersi. Onkol Prakt 
Klin Edu. 2020; 6(5): 297–352.
10. Ter Welle-Butalid ME, Vriens IJ, Derhaag JG, et al. Counseling young 
women with early breast cancer on fertility preservation. J Assist Reprod 
Genet. 2019; 36(12): 2593–2604, doi: 10.1007/s10815-019-01615-6, 
indexed in Pubmed: 31760547.
